by Regina Lynn Preciado | Nov 30, 2021
The COVID-19 pandemic put tremendous pressure on drug-development organizations to accelerate product development far beyond anyone’s wildest roadmaps. “The fast-track part [of producing COVID-19 vaccines] were regulatory approvals, funding, data analysis and...
by Regina Lynn Preciado | Oct 27, 2021
Recently, I was working through some challenges with a custom schema that supports the structured content model for one of my pharma customers. I needed to take an existing document and lay it out with both the old schema and the new schema and make sure all the...
by Regina Lynn Preciado | Oct 10, 2021
A reuse map is a blueprint for planned content reuse. Planned content reuse means that you identify ahead of time exactly which pieces of content will be reused in a specific output. With planned content reuse, authors do not have to do anything to make the reuse...
by Regina Lynn Preciado | Aug 30, 2021
A question came up recently in a conversation about structured authoring and a migration into a component content management system: “If we’re not going to reuse this content, and it is always entirely unique, do we still need to chunk it into components?” The short...
by Regina Lynn Preciado | Jun 25, 2021
I’ve had more than one conversation over the past several years about whether pharmaceutical companies were “ready” for structured content. After all, many of the benefits of structured content roll up into one key business need: scale. And scale — the ability...
Buy this Book to learn exactly what it takes to deliver personalized experiences at scale.